Hypertrophic osteoarthropathy (HOA) is a syndrome that consists of periostitis, digital clubbing, and painful polyarthropathy. The management and prognosis of HOA is dependent on the underlying disease process. Recognising and treating it accordingly will reduce the symptom burden of patients. We present a case of a patient diagnosed with non-small cell lung cancer and HOA suffering from severe pain, and review specific therapies for the management of HOA-related pain.
Introduction
Hypertrophic osteoarthropathy is a syndrome that consists of periostitis, digital clubbing, and painful polyarthropathy. Its symptoms may be disabling and are reportedly difficult to manage effectively with conventional analgesia [1, 2] . Recognising and treating it accordingly will reduce the symptom burden of patients.
Sometimes palliation is the mainstay of treatment for cancer patients, and alleviating pain becomes very challenging for the physicians. Hypertrophic osteoarthropathy is such a painful condition occurring mainly in patients with primary lung cancer and paraneoplastic syndromes, and pain in this condition is often resistant to conventional analgesic medications [3, 4] . Herein, in order to manage HOA-related symptoms in a patient diagnosed with non-small cell lung cancer, we present a case report and address possible therapies for pain relief.
Case report
A 64-year-old male presented with a medical history of arterial hypertension for the last 10 years treated with angiotensin-II-receptor antagonists (sartans), and he was a heavy smoker. Initially affecting both ankles with severe pain and swelling affecting several joints over the course of two weeks, it then progressed to the shoulders, elbows, wrists, hands, hips, knees, and feet. The patient did not report any chills, fever, or other nonspecific symptoms except a loss of 25 pounds (11.3 kg) of weight over the course of six months.
Behaviour disorders, such as irritability and memory loss, were observed to have developed over the course of one month. The physical examination performed only revealed an oedema and a warmth of the aforementioned joints and grade 4 clubbing, as evident by loss of Lovibond's angle ( Fig. 1 and 2) .
Chest radiography revealed a mass in the right lower lobe and emphysematous changes. Laboratory tests showed a microcytic anaemia (haemoglobin: 11.5 g/dL, mean corpuscular volume: 69), a raised platelet count (426), and elevated C reactive protein (63.9). Other blood tests including renal biochemistry, liver function tests, bone profile, and uric acid were within normal limits. Rheumatoid screening was negative, and all tumour markers were within normal range. Computer tomography scan confirmed presence of nodular mass in lower lobe of the right lung and mediastinal lymphadenopathy ( Fig. 3) . Head scan revealed a 2 cm round mass corresponding to the metastasis in the right temporal area with oedema. Bronchofiberoscopy with biopsy led to a diagnosis of NSCLC infiltrating the tracheal bifurcation and both bronchi. Bone scintigraphy using technetium-99 showed a symmetrical and regular increase of the radiopharmaceutical absorption in hand and wrist joints ( Fig. 4) . A diagnosis of lung carcinoma with paraneoplastic HOA was made. The patient was subjected to radiotherapy due to cerebral metastasis and was treated with erlotinib.
On admission the patient suffered from severe pain. A fentanyl patch (50 µg/h) with ibuprofen 800 mg three times daily and prednisone 40 mg daily was started. Even though the regimen was correctly administered, severe joint pain persisted and i.v. continuous infusion of morphine titrated up to 200 mg per day was started. The patient's analgesic requirements rapidly escalated, with minimal benefit from a combination of morphine, ibuprofen, and prednisone. It was decided to start an i.v. infusion of 4 mg of zoledronic acid. The patient experienced significant pain relief from within 48 h of starting the infusion. He was weaned off the i.v. morphine. Fentanyl patch, ibuprofen 600 mg three times per day, and a dosage of 15 to 30 mg of morphine sulphate was administered every four hours with positive results. The patient's pain remained mild and he did not receive any subsequent bisphosphonate infusions, remaining comfortable and dying 40 days after admission to the palliative care unit. 
Discussion
Hypertrophic pulmonary osteoarthropathy is a syndrome characterised by abnormal proliferation of the cutaneous and osseous tissues at the distal part of the extremities. It occurs as a primary or secondary syndrome [1, 2] . The primary or familial form of HOA is inherited as an autosomal dominant trait and generally manifests in childhood. The secondary form is more frequently observed in adults and is related with such conditions as lung cancer, cystic fibrosis, congenital heart disease, and an assortment of other disorders. Among malignancy-related HOA, pulmonary malignancies make up 80% of reported HOA cases, out of which the majority are NSCLC, for example adenocarcinoma or squamous cell carcinoma [3] [4] [5] .
Pathogenesis of HOA still remains unclear, with several mechanisms being proposed. VEGF, platelet-derived growth factor, prostaglandin E, and other cytokines may play a role in causing the periostitis and digital changes in HOA [4, 5] . Receptors for VEGF have been found in subperiosteal bone-forming cells, and high levels of VEGF have been found in virtually all the diseases associated with secondary HOA (but not seen in congenital cyanotic heart disease) and in primary HOA; these levels correlate to levels of underlying disease activity. Patients with lung cancer and HOA have been shown to have significantly higher serum levels of VEGF than those who do not have HOA [2, 5, 6] .
The management and prognosis of HOA is dependent on the underlying disease process. Surgical removal of the tumour or reduction in tumour bulk with chemotherapy can improve or resolve HOA in some cases. The tyrosine kinase inhibitor gefitinib has also been shown to resolve symptoms as well as providing resolution of radiological findings. The current management of the symptoms of HOA includes conventional analgesia working up the WHO analgesic ladder, as well as non-steroidal medication and practical measures such as physiotherapy [1, 3, 4] .
Standard analgesic therapy is difficult to establish and manage. It is usually a combination of NSAIS, opioids, and corticosteroids. However, patients respond differently, and sometimes total relief is not achieved and the intense arthralgia subsists. In cases where pain is refractory to conventional analgesia, case studies have reported success with bisphosphonates including zoledronic acid and pamidronate [7] [8] [9] .
Nitrogen-containing bisphosphonates like zoledronic acid promote osteoclast apoptosis by inhibiting the activity of farnesyl pyrophosphate synthase, thus relieving pain in these conditions. They also act by inhibiting osteocyte apoptosis and targeting monocytes. In addition, bisphosphonates may also have antitumour, anti-inflammatory, and antiangiogenic effects and reduce VEGF in patients with metastatic solid tumours, but the exact mechanism of action of bisphosphonates in HOA remains unclear [8, 9] .
Case studies show that octreotide, a synthetic analogue of somatostatin and inhibitor of growth hormone, can alleviate HOA-related pain successfully. They also describe the involvement of VEGF in the pathogenesis of HOA, which explains the effect of octreotide as an inhibitor of VEGF production and of subsequent proliferation in cutaneous and osseous tissues. The inhibition of the aforementioned factor may be a mechanism to relieve the symptoms in patients with HOA. [10] . Recent research has shown that cisplatin and other chemotherapeutic agents like doxorubicin directly reduce VEGF transcription, indicating a different mechanism of action of such drugs in hypertrophic osteoarthropathy [11] .
Conclusions
Palliative care physicians and nurses should be able to recognise HOA as a symptom related to lung malignancies. It is important to know the viable means of management of HOA-related pain. 
Streszczenie
Osteoartropatia przerostowa (HOA, hypertrophic osteoarthropathy) to zespół obejmujący zapalenie okostnej, tak zwane palce pałeczkowate oraz bolesną poliartropatię. Postępowanie i rokowanie w przypadku HOA jest uzależnione od przebiegu choroby podstawowej. Odpowiednie rozpoznanie i leczenie zmniejsza uciążliwość objawów u pacjentów. W pracy przedstawiono przypadek pacjenta, u którego zdiagnozowano niedrobnokomórkowy nowotwór płuc i HOA, borykającego się z silnym bólem, oraz dokonano przeglądu konkretnych metod leczenia bólu związanego z HOA. 
Wstęp
Osteoartropatia przerostowa to zespół obejmujący zapalenie okostnej, tak zwane palce pałeczkowate oraz bolesną poliartropatię. Objawy choroby mogą prowadzić do kalectwa, a chorzy zgłaszają, że trudno je złagodzić za pomocą konwencjonalnych metod analgezji. Odpowiednie rozpoznanie i leczenie zmniejsza uciążliwość objawów u pacjentów.
Niejednokrotnie leczenie paliatywne jest głównym celem leczenia pacjentów chorych na nowotwory, a złagodzenie bólu staje się największym wyzwaniem dla lekarzy. Osteoartropatia przerostowa jest scho-rzeniem niezwykle bolesnym, występującym głównie u pacjentów z pierwotnym nowotworem płuc, zespołami paranowotworowymi, a ból w tym przypadku jest często oporny na działanie konwencjonalnych leków przeciwbólowych [3, 4] .
W niniejszym artykule przedstawiono przypadek pacjenta, u którego zdiagnozowano NSCLC i HOA, borykającego się z silnym bólem, oraz dokonano przeglądu konkretnych metod leczenia bólu związanego z HOA.
Opis przypadku
Mężczyzna 64-letni z nadciśnieniem tętniczym w wywiadzie, od 10 lat leczony sartanem, nałogowy palacz zgłosił się do szpitala po 2 tygodniach odczuwania silnego bólu, z towarzyszącym obrzękiem stawów. Początkowo objawy wystąpiły w obu kostkach, następnie przeszły do stóp, kolan, bioder, rąk, nadgarstków, łokci i ramion. Chory nie zgłaszał gorączki, dreszczy czy innych objawów ogólnoustrojowych, ale w ciągu ostatnich 6 miesięcy odnotował około 11-kilogramowy spadek masy ciała. Zaobserwowano postępujące w ciągu ostatniego miesiąca zaburzenia zachowania, takie jak rozdrażnienie i utrata pamięci. W badaniu fizykalnym bez zmian, za wyjątkiem znacznego obrzęku i ciepłoty nadgarstków, kolan, kostek Badanie radiograficzne klatki piersiowej wykazało obecność zmiany w prawym dolnym płacie i zmiany rozedmowe. Badania laboratoryjne wykazały anemię mikrocytarną (hemoglobina: 11,5 g/dl, średnia objętość komórkowa: 69), podwyższona liczba płytek krwi (426) i podwyższone białko C-reaktywne (63,9). Inne wyniki badań krwi, w tym biochemia nerek, testy wątrobowe, profil kostny i kwas moczowy mieściły się w granicach normy. Badania przesiewowe w kierunku chorób reumatoidalnych dały wynik ujemny, a wszystkie markery nowotworowe mieściły się w granicach normy. Tomografia komputerowa potwierdziła obecność zmiany guzowatej w dolnym płacie prawego płuca i limfadenopatii śródpiersia (ryc. 3). Tomografia głowy ukazała 2-centymetrową okrągłą zmianę odpowiadającą przerzutom w prawym obszarze skroniowym, z obrzękiem. Bronchofiberoskopia z biopsją pozwoliła na zdiagnozowanie NSCLC, naciekającego rozwidlenie tchawicy i oba oskrzela. Scyntygrafia układu kostnego z zastosowaniem Technetium-99 wykazała symetryczny i regularny wzrost wchłaniania radiofarmaceutyków w stawach rąk i nadgarstków (ryc. 4). Rozpoznano nowotwór płuc z paranowotworową HOA. Pacjenta poddano radioterapii z powodu przerzutów do mózgu i wdrożono leczenie erlotinibem.
